Corcept Therapeutics News

Express News | Corcept Therapeutics Inc - Targets Year-End for Catalyst Treatment Data Release

ReutersApr 29 08:04 ET

Express News | Corcept Completes Enrollment in Phase 4 Catalyst Trial

ReutersApr 29 08:00 ET

Those Who Invested in Corcept Therapeutics (NASDAQ:CORT) Five Years Ago Are up 82%

When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns.

Simply Wall StApr 25 06:11 ET

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update

GlobeNewswireApr 24 16:05 ET

Express News | HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $38 Price Target

Moomoo 24/7Apr 23 13:28 ET

Corcept Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 58.33% HC Wainwright & Co. → $38 Reiterates Buy → Buy 02/16/2024 75% Truist Securities $36 → $4

BenzingaApr 23 13:27 ET

20 Companies Screened for Quality in a Cheap -2-

CarGurus Inc. Class A CARG 13.9% 0.0% 28.5% 4.8% 12.0% Inter

MarketWatchApr 23 10:08 ET

Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TipRanksApr 23 07:20 ET

Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter

Monday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in

BenzingaApr 22 12:36 ET

Corcept Falls After Phase 3 Results on Cushing's Candidate Doesn't Include Some Data

Seeking AlphaApr 22 11:22 ET

Express News | Corcept Therapeutics Inc: Relacorilant Was Well Tolerated

Moomoo 24/7Apr 22 08:05 ET

Express News | Corcept Therapeutics: Remain on Track to Submit Our Nda This Qtr

Moomoo 24/7Apr 22 08:05 ET

Express News | Corcept Therapeutics Inc: No Cases of Relacorilant-Induced Endometrial Hypertrophy With or Without Vaginal Bleeding Were Seen

Moomoo 24/7Apr 22 08:04 ET

Express News | Corcept Therapeutics: Statistically Significant Improvements in Hypertension, Hyperglycemia and Other Key Secondary and Exploratory Endpoints

Moomoo 24/7Apr 22 08:03 ET

Express News | Corcept Therapeutics Says Patients In The Open-Label Phase Exhibited Clinically Meaningful And Statistically Significant Improvements In Hypertension, Hyperglycemia And Other Key Secondary And Exploratory Endpoints

Moomoo 24/7Apr 22 08:03 ET

Express News | Corcept Therapeutics: Patients in Open-Label Phase Exhibited Clinically Meaningful and Statistically Significant Improvements

Moomoo 24/7Apr 22 08:02 ET

Express News | Corcept Therapeutics: Grace's Maintenance of Glycemic Control Is Key Secondary Endpoint

Moomoo 24/7Apr 22 08:02 ET

Express News | Corcept Therapeutics: Grace's Primary Endpoint Is Maintenance of Blood Pressure Control in "Randomized Withdrawal" Phase

Moomoo 24/7Apr 22 08:01 ET

Express News | Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 Grace Trial in Patients With Cushing’s Syndrome

Moomoo 24/7Apr 22 08:00 ET

Express News | Corcept Completes Enrollment In Phase 2 DAZALS Trial In Patients With Amyotrophic Lateral Sclerosis

Moomoo 24/7Apr 15 08:09 ET